A critical literature review of health economic evaluations in pertussis booster vaccination

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 1, 2012, Pages 71-94

  Millier, Aurelie ^a   Aballea, Samuel ^a   Annemans, Lieven ^b,c   Toumi, Mondher ^d   Quilici, Sibilia ^e  

^a CREATIV CEUTICAL   (France)

^b GHENT UNIVERSITY   (Belgium)

^c FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^d UNIVERSITÉ LYON 1   (France)

^e SANOFI PASTEUR   (France)

Author keywords

adolescent; adults; cost effectiveness; economic evaluation; pertussis booster vaccination

Indexed keywords

PERTUSSIS VACCINE;

ASYMPTOMATIC INFECTION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HERD IMMUNITY; HUMAN; INCIDENCE; INFECTION RATE; OUTCOME ASSESSMENT; PERTUSSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; VACCINATION;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION, SECONDARY; MODELS, ECONOMIC; PERTUSSIS VACCINE; RESEARCH DESIGN; WHOOPING COUGH;

EID: 84856431060     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.94     Document Type: Review

References (39)

1. Edwards KM. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended? Clin. Infect. Dis. 32(12), 1698-1699 (2001). (Pubitemid 32531997)
2. Black RE et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375(9730), 1969-1987 (2010).
3. Floret D. Pediatric deaths due to community-acquired bacterial infection. Survey of French pediatric intensive care units. Arch. Pediatr. 8(Suppl. 4), S705-S711 (2001).
4. Zepp F, Heininger U, Mertsola J et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11(7), 557-570 (2011).
5. Fonteneau L, Guthmann JP, Collet M, Vilain A, Herbet J, Lévy-Bruhl D. Vaccination coverage estimated based on data found in 24th month health certificates of infants, France, 2004-2007. Bull. Epidemiologique Hebdomadaire 31-32, 329-333 (2010).
6. De Greeff S, De Melker H, Mooi F. Pertussis in the Netherlands. Nederlands Tijdschrift Voor Geneeskunde 154, A1383 (2010).
7. Von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect. Dis. 2(12), 744-750 (2002). (Pubitemid 35434559)
8. Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. 185(10), 1448-1453 (2002). (Pubitemid 34507967)
9. Guris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults. Clin. Infect. Dis. 28(6), 1230-1237 (1999). (Pubitemid 29272795)
10. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25(14), 2634-2642 (2007). (Pubitemid 46400927)
11. Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(40), 385-400 (2010).
12. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on immunization practices, 2010. MMWR Morb. Mortal. Wkly Rep. 60(1), 13-15 (2011).
13. De Vries R, Kretzschmar M, Schellekens JFP et al. Cost-effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS One 5(10), 13392 (2010).
14. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien J. Pertussis immunization of adolescents in the US: an economic evaluation. Paediatr. Infect. Dis. J. 24(Suppl. 5), 75-82 (2005).
15. Lee GM, LeBaron CW, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 115(6), 1675-1684 (2005). (Pubitemid 43843179)
16. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 4(7), e6284 (2009).
17. Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22(31-32), 4215-4227 (2004). (Pubitemid 39330343)
18. Iskedjian M, Walker JH, De Serres G, Einarson TR. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatr. Drugs 7(2), 123-136 (2005). (Pubitemid 40733722)
19. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316-1330 (2002). (Pubitemid 34131673)
20. Lee G, Riffelmannd M, Von Konig C. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 26(29-30), 3673-3679 (2008).
21. Westra TA, De Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin. Ther. 32(8), 1479-1495 (2010).
22. Scuffham PA, McIntyre PB. Pertussis vaccination strategies for neonates - an exploratory cost-effectiveness analysis. Vaccine 22(21-22), 2953-2964 (2004). (Pubitemid 38900675)
23. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin. Infect. Dis. 39(1), 20-28 (2004). (Pubitemid 38879544)
24. Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr. Infect. Dis. J. 24(Suppl. 6), 127-133 (2005).
25. Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am. J. Prev. Med. 32(3), 186-193 (2007).
26. Wendelboe AM, Njamkepo E, Bourillon A et al. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26(4). 293-299 (2007). (Pubitemid 46596651)
27. Cherry JD. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 25(4), 361-362 (2006).
28. Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual. Life Outcomes 3, 17 (2005).
29. Murray CJ. Rethinking DALYs. In:The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 . Murray CJ, Lopez AD (Eds). Harvard School of Public Health, MA, USA (1996).
30. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Murray CJ, Lopez AD (Eds). Harvard School of Public Health, MA, USA (1996).
31. Stouthard M, Essink-Bot M, Bonsel G, Barendregt J, Kramers P. Disability Weights for Diseases in The Netherlands. Department of Public Health, Erasmus University, Rotterdam, The Netherlands (1997).
32. Lavine JS, King AA, Bjoørnstad ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc. Natl Acad. Sci. USA 108(17), 7259-7264 (2011).
33. Plotkin S. The global pertussis initiative: process overview. Pediatr. Infect. Dis. J. 24(5), 7-9 (2005).
34. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J. Health. Econ. 12(4), 459-467 (1993). (Pubitemid 24037070)
35. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 9(2), 113-120 (1996). (Pubitemid 26029974)
36. Bala MV, Zarkin GA. Application of cost-effectiveness analysis to multiple products: a practical guide. Am. J. Manag. Care 8(3), 211-218 (2002). (Pubitemid 34256631)
37. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 29(5), 371-386 (2011).
38. Roiz J, Brisson M. Cost-effectiveness of pertussis adolescent booster in the netherlands: a dynamic model based analysis. Presented at: 29th Annual Meeting of the European Society for Pediatric Infectious Diseases. The Hague, The Netherlands, 7-11 June 2011.
39. Weinstein MC, O'Brien B, Hornberger J et al. ISPOR task force on good research practices - modeling studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value Health 6(1), 9-17 (2003) (Pubitemid 36228345)